Literature DB >> 32232524

Deep learning assisted differentiation of hepatocellular carcinoma from focal liver lesions: choice of four-phase and three-phase CT imaging protocol.

Wenqi Shi1, Sichi Kuang1, Sue Cao1, Bing Hu1, Sidong Xie1, Simin Chen1, Yinan Chen2, Dashan Gao3, Yunqiang Chen3, Yajing Zhu2, Hanxi Zhang1, Hui Liu2, Meng Ye2, Claude B Sirlin4, Jin Wang5.   

Abstract

PURPOSE: To evaluate whether a three-phase dynamic contrast-enhanced CT protocol, when combined with a deep learning model, has similar accuracy in differentiating hepatocellular carcinoma (HCC) from other focal liver lesions (FLLs) compared with a four-phase protocol.
METHODS: Three hundred and forty-two patients (mean age 49.1 ± 10.5 years, range 19-86 years, 65.8% male) scanned with a four-phase CT protocol (precontrast, arterial, portal-venous and delayed phases) were retrospectively enrolled. A total of 449 FLLs were categorized into HCC and non-HCC groups based on the best available reference standard. Three convolutional dense networks (CDNs) with the input of four-phase CT images (model A), three-phase images without portal-venous phase (model B) and three-phase images without precontrast phase (model C) were trained on 80% of lesions and evaluated in the other 20% by receiver operating characteristics (ROC) and confusion matrix analysis. The DeLong test was performed to compare the areas under the ROC curves (AUCs) of A with B, B with C, and A with C.
RESULTS: The diagnostic accuracy in differentiating HCC from other FLLs on test sets was 83.3% for model A, 81.1% for model B and 85.6% for model C, and the AUCs were 0.925, 0.862 and 0.920, respectively. The AUCs of models A and C did not differ significantly (p = 0.765), but the AUCs of models A and B (p = 0.038) and of models B and C (p = 0.028) did.
CONCLUSIONS: When combined with a CDN, a three-phase CT protocol without precontrast showed similar diagnostic accuracy as a four-phase protocol in differentiating HCC from other FLLs, suggesting that the multiphase CT protocol for HCC diagnosis might be optimized by removing the precontrast phase to reduce radiation dose.

Entities:  

Keywords:  Artificial intelligence; Computed tomography (CT); Deep learning; Differential diagnosis; Hepatocellular carcinoma; Radiation dosage

Year:  2020        PMID: 32232524     DOI: 10.1007/s00261-020-02485-8

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  25 in total

1.  Value of the unenhanced phase for detection of hepatocellular carcinomas 3 cm or less when performing multiphase computed tomography in patients with cirrhosis.

Authors:  Deirdre J Doyle; Martin E O'Malley; Hyun-Jung Jang; Kartik Jhaveri
Journal:  J Comput Assist Tomogr       Date:  2007 Jan-Feb       Impact factor: 1.826

Review 2.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 3.  Strategies for Reducing Radiation Dose in CT for Pediatric Patients: How We Do It.

Authors:  Anh-Vu Ngo; Abbey J Winant; Edward Y Lee; Grace S Phillips
Journal:  Semin Roentgenol       Date:  2018-02-06       Impact factor: 0.800

Review 4.  Advances in computed tomography and magnetic resonance imaging of hepatocellular carcinoma.

Authors:  Tiffany Hennedige; Sudhakar K Venkatesh
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 5.  Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines.

Authors:  Carmen Ayuso; Jordi Rimola; Ramón Vilana; Marta Burrel; Anna Darnell; Ángeles García-Criado; Luis Bianchi; Ernest Belmonte; Carla Caparroz; Marta Barrufet; Jordi Bruix; Concepción Brú
Journal:  Eur J Radiol       Date:  2018-01-31       Impact factor: 3.528

6.  How much dose can be saved in three-phase CT urography? A combination of normal-dose corticomedullary phase with low-dose unenhanced and excretory phases.

Authors:  Pär Dahlman; Aart J van der Molen; Mats Magnusson; Anders Magnusson
Journal:  AJR Am J Roentgenol       Date:  2012-10       Impact factor: 3.959

7.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

Review 8.  Strategies for reducing radiation dose in CT.

Authors:  Cynthia H McCollough; Andrew N Primak; Natalie Braun; James Kofler; Lifeng Yu; Jodie Christner
Journal:  Radiol Clin North Am       Date:  2009-01       Impact factor: 2.303

9.  Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning.

Authors:  Nicolas Coudray; Paolo Santiago Ocampo; Theodore Sakellaropoulos; Navneet Narula; Matija Snuderl; David Fenyö; Andre L Moreira; Narges Razavian; Aristotelis Tsirigos
Journal:  Nat Med       Date:  2018-09-17       Impact factor: 53.440

Review 10.  Intra-individual diagnostic image quality and organ-specific-radiation dose comparison between spiral cCT with iterative image reconstruction and z-axis automated tube current modulation and sequential cCT.

Authors:  Holger Wenz; Máté E Maros; Mathias Meyer; Joshua Gawlitza; Alex Förster; Holger Haubenreisser; Stefan Kurth; Stefan O Schoenberg; Christoph Groden; Thomas Henzler
Journal:  Eur J Radiol Open       Date:  2016-07-26
View more
  6 in total

Review 1.  Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma.

Authors:  Julien Calderaro; Tobias Paul Seraphin; Tom Luedde; Tracey G Simon
Journal:  J Hepatol       Date:  2022-06       Impact factor: 30.083

Review 2.  Role of three-dimensional printing and artificial intelligence in the management of hepatocellular carcinoma: Challenges and opportunities.

Authors:  Chrysanthos D Christou; Georgios Tsoulfas
Journal:  World J Gastrointest Oncol       Date:  2022-04-15

Review 3.  Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine.

Authors:  Nurbubu T Moldogazieva; Innokenty M Mokhosoev; Sergey P Zavadskiy; Alexander A Terentiev
Journal:  Biomedicines       Date:  2021-02-06

Review 4.  Artificial intelligence in gastroenterology and hepatology: Status and challenges.

Authors:  Jia-Sheng Cao; Zi-Yi Lu; Ming-Yu Chen; Bin Zhang; Sarun Juengpanich; Jia-Hao Hu; Shi-Jie Li; Win Topatana; Xue-Yin Zhou; Xu Feng; Ji-Liang Shen; Yu Liu; Xiu-Jun Cai
Journal:  World J Gastroenterol       Date:  2021-04-28       Impact factor: 5.742

Review 5.  Deep learning in hepatocellular carcinoma: Current status and future perspectives.

Authors:  Joseph C Ahn; Touseef Ahmad Qureshi; Amit G Singal; Debiao Li; Ju-Dong Yang
Journal:  World J Hepatol       Date:  2021-12-27

6.  Hepatocellular carcinoma surveillance: current practice and future directions.

Authors:  Joseph C Ahn; Yi-Te Lee; Vatche G Agopian; Yazhen Zhu; Sungyong You; Hsian-Rong Tseng; Ju Dong Yang
Journal:  Hepatoma Res       Date:  2022-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.